BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang H, Song G, Zhang Z, Song H, Tang X, Deng A, Wang W, Wu L, Qin H. Colitis Is Effectively Ameliorated by (±)-8-Acetonyl-dihydrocoptisine via the XBP1-NF-κB Pathway. Front Pharmacol 2017;8:619. [PMID: 28928666 DOI: 10.3389/fphar.2017.00619] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Chen JH, Wu CH, Chiang CK. Therapeutic Approaches Targeting Proteostasis in Kidney Disease and Fibrosis. Int J Mol Sci 2021;22:8674. [PMID: 34445377 DOI: 10.3390/ijms22168674] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Shi M, Chai Y, Zhang J, Chen X. Endoplasmic Reticulum Stress-Associated Neuronal Death and Innate Immune Response in Neurological Diseases. Front Immunol 2021;12:794580. [PMID: 35082783 DOI: 10.3389/fimmu.2021.794580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
3 Tang X, Li X, Wang Y, Zhang Z, Deng A, Wang W, Zhang H, Qin H, Wu L. Butyric Acid Increases the Therapeutic Effect of EHLJ7 on Ulcerative Colitis by Inhibiting JAK2/STAT3/SOCS1 Signaling Pathway. Front Pharmacol 2019;10:1553. [PMID: 32038241 DOI: 10.3389/fphar.2019.01553] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
4 Xie C, Cen D, Ren Z, Wang Y, Wu Y, Li X, Han G, Cai X. FeS@BSA Nanoclusters to Enable H2S-Amplified ROS-Based Therapy with MRI Guidance. Adv Sci (Weinh) 2020;7:1903512. [PMID: 32274323 DOI: 10.1002/advs.201903512] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 24.0] [Reference Citation Analysis]
5 Lu PD, Zhao YH. Targeting NF-κB pathway for treating ulcerative colitis: comprehensive regulatory characteristics of Chinese medicines. Chin Med 2020;15:15. [PMID: 32063999 DOI: 10.1186/s13020-020-0296-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
6 Yang Y, Vong CT, Zeng S, Gao C, Chen Z, Fu C, Wang S, Zou L, Wang A, Wang Y. Tracking evidences of Coptis chinensis for the treatment of inflammatory bowel disease from pharmacological, pharmacokinetic to clinical studies. J Ethnopharmacol 2021;268:113573. [PMID: 33181286 DOI: 10.1016/j.jep.2020.113573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Song H, Tang X, Li X, Wang Y, Deng A, Wang W, Zhang H, Qin H, Wu L. HLJ2 Effectively Ameliorates Colitis-Associated Cancer via Inhibition of NF-κB and Epithelial-Mesenchymal Transition. Drug Des Devel Ther 2020;14:4291-302. [PMID: 33116416 DOI: 10.2147/DDDT.S262806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Choo J, Heo G, Pothoulakis C, Im E. Posttranslational modifications as therapeutic targets for intestinal disorders. Pharmacol Res 2021;165:105412. [PMID: 33412276 DOI: 10.1016/j.phrs.2020.105412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Royal JM, Oh YJ, Grey MJ, Lencer WI, Ronquillo N, Galandiuk S, Matoba N. A modified cholera toxin B subunit containing an ER retention motif enhances colon epithelial repair via an unfolded protein response. FASEB J 2019;33:13527-45. [PMID: 31560862 DOI: 10.1096/fj.201901255R] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]